Table 1.
Summary of clinical and laboratory findings in 4 patients
| Case 1 | Case 2 | Case 3 | Case 4 | |
|---|---|---|---|---|
| Age/Sex | 73/F | 61/M | 69/M | 81/F |
| Stage | IV | IV | IV | IV |
| CBC | HGB 11.9 g/dL WBC 96.2 ×109/L Platelet 121 ×109/L | HGB 6.6 g/dL WBC 438.5 ×109/L Platelet 59 ×109/L | HGB 9.1 g/dL WBC 21.2 ×109/L Platelet 18 ×109/L | HGB 9.4 g/dL WBC 84.7 ×109/L Platelet 141 ×109/L |
| Absolute lymphocyte count in PB | 86 ×109/L | 425 ×109/L | 14 ×109/L | 51 ×109/L |
| Bone marrow involvement | ND | ND | Yes | Yes |
| Lymphadenopathy | Yes, generalized | No | No | No |
| Splenomegaly | Yes, 15 cm by CT | Yes, 18 cm by CT | Yes, 20 cm by CT | Yes, 1 cm below left costal margin |
| Serum LDH | 688 U/L | 17870 U/L | 800 U/L | 3094 U/L |
| Therapy | R-CHOP Bendamustine and Rituxan | EPOCH Hyper-CVAD | CHOP Hyper-CVAD Autologous HSCT | None |
| Outcome, months | CR, 17 | CR, 4 | Persistent disease, 13 | In hospice, 3 |
M, male; F, female; CBC, Complete Blood Count; PB, peripheral blood; ND, not determined; CT, computerized axial tomography; CR, complete remission; R, Rituximab; CHOP, Cytoxan, adriamycin, vincristine, and prednisone; EPOCH, etoposide, prednisone, vincristine, cytoxan, and doxorubicin; Hyper-CVAD, cytoxan, adriamycin, vincristine, prednisone alternating with high dose cytarabine and methotrexate; HSCT, hematopoietic stem cell transplant.